Financial Performance - The company reported a slight revenue increase from RMB 735 million to RMB 747 million compared to 2023, despite a challenging market environment[11]. - The group's revenue for the year ended December 31, 2024, was approximately RMB 74.7 million, an increase from RMB 73.5 million in 2023[16]. - The net loss for the year ended December 31, 2024, was approximately RMB 32.6 million, compared to a net loss of RMB 13.6 million for the year ended December 31, 2023[16]. - The company's gross profit decreased by approximately 17.4% to about RMB 27.0 million, with a gross margin of approximately 36.1%, down from 44.4% in the previous fiscal year[36]. - Other income and gains decreased by approximately 27.1% to about RMB 4.3 million, mainly due to reduced bank interest income[37]. - Administrative expenses increased by approximately 60.3% to about RMB 36.7 million, primarily due to share-based compensation for senior management and costs related to acquisitions[39]. - The company recorded a loss attributable to owners of approximately RMB 32.4 million for the reporting period, compared to a loss of RMB 13.6 million in the previous fiscal year[41]. Patient Metrics - The number of active dental patients increased from 50,324 to 61,777 during the year[11]. - The total number of active patients increased by 22.8%, from 50,324 in 2023 to 61,777 in 2024[22]. - The number of active patients at Wenzhou Hospital increased from 27,958 in 2023 to 28,366 in 2024[22]. - The dental service provider maintains a patient acceptance rate of 68% in Wenzhou, higher than the national average of 52%[10]. Operational Strategy - The company aims to enhance medical technology and service quality in response to upcoming dental pricing reforms announced by the National Medical Insurance Bureau[11]. - Future plans include focusing on precise diagnosis and personalized treatment solutions, as well as building a smart training platform for professional talent[12]. - The company intends to deepen cooperation with international medical institutions while expanding into overseas markets[12]. - The group plans to optimize its cost structure and improve operational efficiency to attract price-sensitive patients amid increased competition and regulatory changes[17]. - The group is strategically investing in scalable technologies and standardized processes to enhance its ability to provide value-oriented solutions in a changing regulatory environment[25]. - The group aims to innovate its service offerings by integrating advanced technologies, such as AI-driven diagnostics and minimally invasive treatment options[27]. Employee Metrics - The total number of employees increased to 372 as of December 31, 2024, up from 286 as of December 31, 2023, reflecting a growth in workforce[48]. - Employee benefit expenses for the reporting period were approximately RMB 522 million, an increase of RMB 188 million compared to RMB 334 million in the previous fiscal year[48]. - The employee turnover rate for the reporting period is 62%, which is considered slightly high within the industry[198]. - Female employees account for over 75% of the workforce, highlighting the company's commitment to gender equality in hiring and promotion practices[197]. - The total number of employees by age group includes 129 under 25, 118 between 26 and 35, 73 between 36 and 45, 27 between 46 and 55, and 25 aged 56 and above[197]. Corporate Governance - The board of directors is committed to maintaining high standards of corporate governance and business ethics[76]. - The board has established three committees: Audit Committee, Remuneration Committee, and Nomination Committee to oversee specific aspects of the company's affairs[81]. - The company has adopted the standard code of conduct for directors' securities transactions during the reporting period[79]. - The board believes that the risk management and internal control systems are effective and sufficient during the reporting period[130]. - The company has established a mechanism to ensure independent viewpoints are obtained for board decisions, including the review of the proportion and contributions of independent non-executive directors[103]. Environmental, Social, and Governance (ESG) Initiatives - The group emphasizes sustainable development and corporate social responsibility while balancing profitability, environmental, and social impacts[152]. - The group adheres to the Hong Kong Stock Exchange's ESG reporting guidelines, focusing on materiality, quantification, balance, and consistency[155]. - The board is responsible for overseeing ESG-related risks and opportunities, setting strategies, and reviewing performance annually[161]. - The group has identified key environmental, social, and governance issues that may impact its sustainable development, conducting a materiality assessment to evaluate their significance[171]. - The company emphasizes the importance of environmental sustainability and aims to reduce negative impacts on the environment while contributing to sustainable development[175]. Future Plans and Investments - The company plans to consolidate and expand its market position in China[82]. - The company aims to expand its global dental care network and establish chain dental clinics under a new brand name outside Wenzhou[87]. - The company plans to purchase new dental equipment and supplies to enhance the quality of dental services provided[87]. - A dental training center will be established to build a talent pool of dentists and improve service quality[87]. - The company has not established an internal audit function, considering the scale and complexity of its operations[129].

Financial Performance - Revenue increased by approximately 1.6% to about RMB 74.7 million for the year ending December 31, 2024, compared to RMB 73.5 million for the year ending December 31, 2023[4] - Loss before tax was approximately RMB 30.1 million, worsening from a loss of approximately RMB 7.2 million for the year ending December 31, 2023[4] - Loss attributable to equity holders of the company was approximately RMB 32.4 million, compared to a loss of approximately RMB 13.6 million for the year ending December 31, 2023[4] - Basic and diluted loss per share attributable to ordinary equity holders of the parent was approximately RMB 5.57 cents, compared to RMB 2.27 cents for the year ending December 31, 2023[4] - Total comprehensive loss for the year was RMB 31.146 million, compared to RMB 12.206 million for the previous year[6] - The group reported a pre-tax loss of RMB 49,280,000 for 2024, compared to RMB 32,074,000 in 2023, indicating an increase in losses[24] - The net loss for the fiscal year ending December 31, 2024, was approximately RMB 32.6 million, compared to a net loss of RMB 13.6 million for the fiscal year ending December 31, 2023, indicating a significant increase in losses[39] Revenue Breakdown - Revenue from customer contracts for 2024 was RMB 74,680,000, an increase of 1.6% from RMB 73,513,000 in 2023[21] - Revenue for the reporting period was approximately RMB 74.7 million, an increase of about 1.6% compared to the fiscal year ending December 31, 2023, primarily due to contributions from two new facilities[54] - Revenue from the Oral Comprehensive Treatment Department was approximately RMB 30.5 million, a decrease of about 2.2% compared to the previous fiscal year, accounting for approximately 40.8% of total revenue[55] - Revenue from the Orthodontics Department was approximately RMB 14.1 million, a decrease of about 2.1% compared to the previous fiscal year, representing about 18.9% of total revenue[56] - Revenue from the Oral Rehabilitation Department was approximately RMB 16.3 million, an increase of RMB 1.4 million, accounting for about 21.8% of total revenue[57] - Revenue from the Implant Dentistry Department was approximately RMB 8.9 million, an increase of about 11.3% compared to the previous fiscal year, indicating a recovery in revenue[58] Expenses and Costs - Gross profit decreased to RMB 26.976 million from RMB 32.655 million, reflecting a decline in profitability[6] - Administrative expenses increased significantly to RMB 36.733 million from RMB 22.940 million, indicating rising operational costs[6] - Sales costs increased by approximately 16.6% to about RMB 47.7 million, attributed to rising employee costs and stock issuance rewards[59] - Selling expenses increased by approximately 10.1% to about RMB 22.8 million, mainly due to increased marketing and promotional expenses[62] - Employee benefits expenses increased to approximately RMB 52.2 million during the reporting period, compared to approximately RMB 33.4 million in the fiscal year 2023, an increase of RMB 18.8 million[72] Assets and Liabilities - Non-current assets increased to RMB 91,889 thousand in 2024 from RMB 80,117 thousand in 2023, representing a growth of 14.5%[8] - Current assets decreased to RMB 98,265 thousand in 2024 from RMB 152,310 thousand in 2023, a decline of 35.5%[8] - Total liabilities increased to RMB 69,756 thousand in 2024 from RMB 66,882 thousand in 2023, reflecting a rise of 4.2%[9] - The company's net asset value decreased to RMB 120,398 thousand in 2024 from RMB 165,545 thousand in 2023, a drop of 27.2%[9] - Cash and cash equivalents decreased to RMB 78,494 thousand in 2024 from RMB 86,827 thousand in 2023, a reduction of 9.5%[8] - The company reported a total equity of RMB 120,398 thousand in 2024, down from RMB 165,545 thousand in 2023, indicating a decrease of 27.2%[9] Taxation - The group's income tax expense for the fiscal year 2024 was RMB 2,478 thousand, a decrease from RMB 6,448 thousand in 2023[29] - The group has no income tax liabilities in Hong Kong for the fiscal year 2024 due to no taxable profits generated[8] - The group has a deferred tax expense of RMB 459 thousand for the fiscal year 2024, down from RMB 4,511 thousand in 2023[29] Corporate Governance and Shareholder Information - The board has resolved not to recommend the payment of a final dividend for the year ending December 31, 2024, compared to a dividend of HKD 0.01 per share for the year ending December 31, 2023[4] - The annual general meeting is scheduled for June 18, 2025, with a suspension of share transfer registration from June 13 to June 18, 2025[82][83] - The company has complied with all corporate governance codes applicable as of December 31, 2024, except for one specific provision[84] - The audit committee consists of three independent non-executive directors, who have reviewed the annual consolidated financial statements for the year ending December 31, 2024[89] Strategic Initiatives - The group is adjusting its business to respond to the national dental procurement policy, which has expanded to orthodontics, pediatric dentistry, and cosmetic dentistry[49] - The group aims to optimize its service offerings and strengthen partnerships with upstream suppliers to maintain service quality while achieving cost efficiency[49] - The group plans to enhance community-centered initiatives, including expanding oral health education programs and supporting vulnerable groups in collaboration with local governments[50] - The group is committed to reducing waste in clinical operations and promoting digital patient engagement tools[50] - The group is strategically investing in scalable technologies and standardized processes to ensure adaptability in a rapidly changing regulatory environment[49] - The group is focused on optimizing its cost structure to attract price-sensitive patients while ensuring service quality[41] - The group is establishing long-term partnerships with dental material suppliers to obtain better purchasing prices and improve internal management efficiency[41]

美皓醫療集團有限 公司 M EIH AO M E DIC AL G R O UP C O., LT D 美 皓 醫 療 集 團 有 限公司 MEIHAO MEDICAL GROUP CO., LTD (Incorporated in the Cayman Islands with limited liability) Stock Code: 1947 INTERIM REPORT 2024 中期報告 （於開曼群島註冊成立的有限公司） 股份代號 : 1947 中期報告 2024 2024 INTERIM REPORT and . tes and of the state of the many of the state of the states of the states of the states of the states of the states of the states of the states of the states of the state o 目錄 | --- | --- | |-------|--------------------------| | | | | 2 | 公司資料 | ...

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 33,797, a decrease of 3.4% from RMB 34,985 for the same period in 2023[3] - Gross profit for the same period was RMB 12,348, down 20.5% from RMB 15,468 in 2023[3] - The company reported a loss before tax of RMB 14,432, compared to a loss of RMB 2,751 in the previous year, indicating a significant increase in losses[3] - Total comprehensive loss for the period was RMB 14,466, compared to a comprehensive income of RMB 1,005 in the same period last year[4] - The company reported a basic and diluted loss per share of RMB 2.51, compared to RMB 0.35 in the previous year, indicating a worsening financial performance[3] - The company reported a basic loss per share attributable to ordinary equity holders of RMB 15,074 thousand for the six months ended June 30, 2024, compared to RMB 2,122 thousand for the same period in 2023, indicating a significant increase in losses[20] - Revenue decreased from RMB 35.0 million for the six months ended June 30, 2023, to RMB 33.8 million for the six months ended June 30, 2024, representing a decline of approximately 3.4%[23] Assets and Liabilities - Non-current assets decreased to RMB 78,172 as of June 30, 2024, from RMB 80,117 as of December 31, 2023[5] - Current assets totaled RMB 146,254, a slight decrease from RMB 152,310 at the end of 2023[5] - The company's cash and cash equivalents increased to RMB 100,462 from RMB 86,827 at the end of 2023, reflecting improved liquidity[5] - Total liabilities increased to RMB 44,255 from RMB 37,959, indicating a rise in financial obligations[5] - The equity attributable to the owners of the parent decreased to RMB 151,504 from RMB 165,178, reflecting a decline in shareholder value[7] - Trade receivables at the end of the reporting period totaled RMB 1,317,789 thousand, a decrease from RMB 1,301,759 thousand as of December 31, 2023[21] - Trade payables at the end of the reporting period amounted to RMB 7,360,000 thousand, up from RMB 6,640,000 thousand as of December 31, 2023, reflecting an increase of approximately 10.9%[22] Revenue Breakdown - Customer contract revenue for the six months ended June 30, 2024, was RMB 33,797 thousand, a decrease of 3.4% from RMB 34,985 thousand in the same period of 2023[12] - Revenue from the Oral Comprehensive Treatment Department was approximately RMB 14.3 million, a decrease of about 4.7% year-on-year, accounting for approximately 42.2% of total revenue[36] - Revenue from the Orthodontics Department was approximately RMB 5.7 million, a decrease of about 6.6% year-on-year, representing about 17.0% of total revenue[37] - Revenue from the Oral Restoration Department was approximately RMB 7.1 million, a decrease of 1.4%, accounting for about 21.0% of total revenue[38] - Revenue from the Implant Department increased to approximately RMB 4.3 million, an increase of RMB 0.4 million or 10.3% year-on-year[39] Operational Changes - The total number of active patients decreased from 30,366 to 29,259, a reduction of 3.6% over the same period[27] - The number of active patients at Wenzhou Hospital decreased from 18,908 to 14,545, a decline of approximately 23.2%[27] - The company operates six private dental hospitals and clinics in Wenzhou, Zhejiang Province, focusing on comprehensive dental services across four main areas[23] - The company has increased advertising expenses to attract more customers in response to the impact of the implant dental collection policy on profit margins[23] - The company has implemented a talent acquisition strategy to ensure sustainable development and maintain existing human resources[23] - The implementation of the dental implant collection policy in China has led to a decrease in the number of visits and average spending per visit, posing long-term challenges for dental service providers[29] Future Strategies - The company is optimistic about its future development prospects despite the current challenges[23] - The company plans to increase investment in marketing efforts to capture market opportunities and strengthen its market position[29] - The company aims to expand its service offerings by establishing specialized pediatric dental hospitals to meet rising demand in Wenzhou[30] - Strategic acquisitions are being sought in Zhejiang Province and neighboring provinces to enhance market presence[30] - The company is focusing on upstream investments in medical device companies to stabilize supply chains and reduce procurement costs[31] - Upgrading the business operation software system will improve data integration and management across six dental hospitals and clinics, enhancing service efficiency[33] - Increased advertising investment is expected to improve business capabilities and customer engagement[33] Corporate Governance and Compliance - The company is committed to maintaining high standards of corporate governance and has adopted all applicable corporate governance codes, except for a specific provision regarding the separation of the roles of chairman and CEO[60][61] - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited interim results for the six months ending June 30, 2024, ensuring compliance with accounting policies and disclosure requirements[64] - The interim report for the six months ending June 30, 2024, will be sent to shareholders and published on the company's website[65] - The company expresses heartfelt thanks to shareholders, management team, employees, and business partners for their support and contributions[66] Employee and Operational Metrics - The company has 323 employees as of June 30, 2024, an increase from 286 employees as of December 31, 2023[53] - Employee benefits expenses for the reporting period amounted to approximately RMB 19.1 million, a decrease of about RMB 1.1 million compared to RMB 20.2 million in the same period of 2023[54] Shareholder Information - The company declared a final dividend of HKD 0.01 per ordinary share, with approximately HKD 5.9 million (approximately RMB 5.4 million) to be paid in cash[19] - The board of directors decided not to declare an interim dividend for the six months ending June 30, 2024, consistent with the previous period[59] - The company completed a global offering of 150,000,000 shares at an issue price of HKD 0.84 per share, which is expected to support future business development and expansion in China[48] - The company issued 154,350 shares of bonus shares on June 26, 2024, which began trading on the Hong Kong Stock Exchange on August 15, 2024[56] - The company implemented a share reward plan on January 16, 2024, purchasing a total of 230,000 shares from January 24 to January 25, 2024, representing approximately 0.038% of the total issued shares[57] - The company completed the acquisition of 98.5% of the shares of a private dental service provider, Le Qing Dental Hospital Limited, on December 19, 2023[58] Risk Management - The company is closely monitoring foreign exchange risks, particularly the impact of RMB and HKD exchange rate fluctuations on its financial position[50] - The company has no significant contingent liabilities or guarantees as of June 30, 2024, consistent with the previous year[52] - There were no significant investments or acquisitions during the reporting period[55]

（於開曼群島註冊成立的有限公司） 股份代號 : 1947 年報 目 錄 | 2 | 公司資料 | | --- | --- | | 4 | 主席致辭 | | 6 | 管理層討論及分析 | | 14 | 董事及高級管理層 | | 19 | 企業管治報告 | | 35 | 環境、社會及管治報告 | | 67 | 董事會報告 | | 93 | 獨立核數師報告 | | 98 | 綜合損益及其他全面收益表 | | 100 | 綜合財務狀況表 | | 102 | 綜合權益變動表 | | 103 | 綜合現金流量表 | | 105 | 財務報表附註 | | 162 | 財務摘要 | | 163 | 釋義 | 公司資料 董事會 執行董事 王曉敏先生 （主席、行政總裁） 鄭蠻女士 （總經理） 獨立非執行董事 黃晞華先生 譚漢珊女士 周健醫生 公司秘書 李忠成先生（HKICPA、ACCA） （於二零二四年三月三十一日辭任） 陳玉穎女士 （於二零二四年三月三十一日獲委任） 上市規則下授權代表 王曉敏先生 李忠成先生 （於二零二四年三月三十一日辭任） 陳玉穎女士 （於二零二四年三月三十一日獲委任） 審核委員會 黃晞華先生 （主席） 周 ...

Financial Performance - Revenue decreased by approximately 42.3% to about RMB 73.5 million, compared to RMB 127.4 million for the year ended December 31, 2022[2]. - The company reported a loss before tax of approximately RMB 7.2 million, a decline from a profit of approximately RMB 40.2 million for the year ended December 31, 2022[2]. - Loss attributable to equity holders of the company was approximately RMB 13.6 million, compared to a profit of approximately RMB 28.5 million for the year ended December 31, 2022[2]. - Basic and diluted loss per share attributable to ordinary equity holders of the parent was approximately RMB 2.27, down from earnings of approximately RMB 6.22 for the year ended December 31, 2022[5]. - The group reported a pre-tax loss of RMB 10,478 thousand for 2023, compared to a loss of RMB 15,204 thousand in 2022, indicating a reduction in losses[25]. - The company's gross profit decreased by approximately 58.2% to about RMB 32.7 million, with a gross profit margin dropping to approximately 44.4% from 61.4% in the previous year[71]. - Other income totaled RMB 5,859 thousand in 2023, down from RMB 9,895 thousand in 2022, primarily due to a significant reduction in government grants[24]. - Income tax expenses for the reporting period were approximately RMB 6.4 million, down from RMB 11.6 million for the year ending December 31, 2022, primarily due to a decline in group revenue and losses from several subsidiaries[76]. Assets and Liabilities - Total non-current assets increased to RMB 80,117,000 from RMB 76,211,000, representing a growth of 3.8% year-over-year[7]. - Current assets decreased to RMB 152,310,000 from RMB 176,507,000, a decline of 13.7% year-over-year[7]. - Total liabilities decreased from RMB 74,967,000 in 2022 to RMB 66,882,000 in 2023, a reduction of 10.7%[7]. - Net assets decreased to RMB 165,545,000 from RMB 177,751,000, reflecting a decline of 6.8% year-over-year[8]. - Cash and cash equivalents decreased to RMB 86,827,000 from RMB 89,529,000, a decrease of 3.1%[7]. - The company's equity attributable to owners remained stable at RMB 165,178,000 compared to RMB 177,372,000 in the previous year[8]. - Current assets decreased from approximately RMB 84.0 million as of December 31, 2022, to approximately RMB 7.0 million as of December 31, 2023, mainly due to the collection of RMB 67.1 million from the global offering[78]. - As of December 31, 2023, the group's current assets net value was approximately RMB 114.4 million, with a current ratio of 4.0 times, down from 4.3 times in the previous year[79]. Revenue Breakdown - Revenue from customer contracts for 2023 was RMB 73,513 thousand, a decrease of 42.4% from RMB 127,408 thousand in 2022[21]. - Revenue from the oral comprehensive treatment department was approximately RMB 31.2 million, a decrease of about 2.5% year-on-year, accounting for approximately 42.5% of total revenue during the reporting period[65]. - Revenue from the orthodontics department was approximately RMB 14.4 million, a decrease of about 27.6% year-on-year, representing about 19.7% of total revenue[66]. - Revenue from the oral restoration department was approximately RMB 14.9 million, a decrease of RMB 13.2 million or 47.0%, accounting for about 20.2% of total revenue[67]. - Revenue from the implant dentistry department was approximately RMB 8.0 million, a significant decrease of RMB 34.2 million or 81.0% due to the implementation of centralized procurement policies[68]. Operational Insights - The company operates primarily in the dental services sector, with all external revenue generated from customers in mainland China[17]. - The company operates five private dental hospitals in Wenzhou, Zhejiang Province, focusing on comprehensive dental services[40]. - The total number of active patients in the five private dental hospitals decreased from 63,659 as of December 31, 2022, to 50,324 as of December 31, 2023, representing a decline of approximately 20.9%[50]. - Wenzhou Hospital contributed the largest share of revenue, accounting for approximately 62.4% of total revenue in 2023, with revenue of RMB 45,820,000[53]. - The implementation of the dental implant procurement policy in China has led to a decrease in the number of dental visits and average spending per visit, negatively impacting the group's dental implant services in the short term[54]. - The company plans to continue expanding its market presence by establishing more private dental hospitals in Wenzhou and seeking potential strategic acquisitions in Zhejiang Province or neighboring provinces[57]. - The group aims to penetrate the pediatric dental market further, believing that demand from child patients will drive growth in the dental service market[57]. - The company is enhancing its operational software systems to improve data integration and management across its five dental hospitals, which will increase service efficiency and reduce operational costs[59]. - The group is focused on providing high-quality dental services to build a good reputation and gain customer trust, which is crucial for competitive advantage[59]. Strategic Initiatives - The board has proposed a final dividend of HKD 0.01 per ordinary share, compared to no dividend for the year ended December 31, 2022[2]. - The company intends to invest in upstream and downstream industry chain extensions to stabilize supply sources and reduce procurement costs, thereby enhancing overall competitiveness[58]. - The establishment of a dental training center is planned to cultivate in-house dental talent and improve service professionalism[62]. - The company is focusing on enhancing service quality and customer satisfaction to gain more customer trust and support, aiming for sustainable development[61]. - The group plans to use net proceeds from global offerings for business expansion and working capital, with no major investment plans set as of December 31, 2023[90]. Governance and Compliance - The company has adhered to all applicable corporate governance codes as of December 31, 2023, except for one specific provision[100]. - The audit committee consists of three independent non-executive directors, with Mr. Huang Xihua as the chairman[106]. - The annual report for the year ending December 31, 2023, will be sent to shareholders and published on the company's website at an appropriate time[107]. - The board expresses heartfelt thanks to shareholders, management team, employees, and business partners for their support and contributions[108].

智通财经APP讯，美皓集团(01947)发布公告，李忠成因其他工作安排已辞任公司公司秘书、公司根据香港联合交易所有限公司证券上市规则第3.05条的授权代表及根据上市规则第19.05(2)条及公司条例(香港法例第622章)第16部在香港代公司接受法律程序文件及通知的代理人，自2024年3月31日起生效。 李先生辞任后，董事会欣然宣布，陈玉颖已获委任为公司的公司秘书、授权代表及法律程序代理人，自2024年3月31日起生效。 ...

Revenue Performance - The total revenue for the six months ended June 30, 2023, decreased to RMB 350 million from RMB 572 million for the same period in 2022, representing a decline of approximately 38.8%[7] - The company's revenue for the reporting period was approximately RMB 35.0 million, a decrease of about 38.8% compared to the same period in 2022[21] - The company reported revenue of RMB 34,985,000 for the six months ended June 30, 2023, a decrease of 38.5% compared to RMB 57,190,000 for the same period in 2022[100] - Customer contract revenue for the six months ended June 30, 2023, was RMB 34,985,000, a decrease of 38.8% compared to RMB 57,190,000 for the same period in 2022[124] Patient Activity - The total number of active patients across the five private dental hospitals decreased from 39,680 to 30,366, a reduction of about 23.5%[13] - The number of active patients at Wenzhou Hospital dropped from 23,811 to 18,908, reflecting a decrease of about 20.5%[13] - The average number of visits for dental services decreased from 29,700 to 23,700, leading to a revenue drop in the oral comprehensive treatment department by approximately 8.5%[22] - Revenue from the orthodontics department decreased by approximately 30.7%, with visits dropping from 5,200 to 3,500[23] - The company noted a gradual increase in patient visits as the impact of COVID-19 diminishes[7] - The company’s subsidiary, Wenzhou Dental Hospital, has reported a 25% increase in patient visits, contributing significantly to overall revenue growth[146] Hospital Revenue Contributions - Revenue contributions from the Wenzhou Hospital accounted for approximately 65.1% of total revenue for the six months ended June 30, 2023, generating RMB 22.76 million[14] - The revenue from the Lucheng Hospital decreased from RMB 13.04 million to RMB 5.05 million, a decline of approximately 61.1%[14] - The revenue from the Wenzhou Oral Hospital decreased from RMB 7.53 million to RMB 3.67 million, a decline of approximately 51.2%[14] - The total revenue from the Longgang Hospital was RMB 2.11 million, contributing 6.0% to total revenue, down from 4.8% in the previous year[14] Financial Performance - Gross profit decreased by approximately 52.6% to about RMB 15.5 million, with the gross margin dropping to approximately 44.2%[28] - The group recorded a loss attributable to the owners of the company of approximately RMB 2.1 million during the reporting period, compared to a profit of RMB 10.9 million for the six months ended June 30, 2022[33] - The company incurred a loss before tax of RMB 2,751,000, compared to a profit of RMB 15,423,000 in the prior year[100] - The net loss attributable to equity holders of the parent was RMB 2,122,000, a significant decline from a profit of RMB 10,863,000 in the same period last year[100] - The company reported a total comprehensive income of RMB 1,005,000 for the six months ended June 30, 2023, compared to RMB 10,873,000 in the previous year[102] Expenses and Cost Management - Selling expenses rose by approximately 63.3% to RMB 9.8 million, attributed to an increase in sales and marketing personnel[30] - Administrative expenses decreased by approximately 9.0% to RMB 10.1 million, influenced by the absence of listing expenses incurred in the previous year[31] - Employee benefit expenses for the reporting period amounted to approximately RMB 20.2 million, an increase of approximately RMB 1.2 million compared to RMB 19.0 million in the same period of 2022[41] - The cost of inventory, consumables, and customized products for the six months ended June 30, 2023, was RMB 5,066,000, down from RMB 6,892,000 in 2022, indicating a reduction of 26.5%[126] Future Outlook and Expansion Plans - The company expressed confidence in future growth due to the gradual recovery from COVID-19 and government support policies[7] - The company plans to expand its dental services in Wenzhou and establish new private dental hospitals to capture rising demand[17] - The company aims to enhance its operational efficiency by upgrading its business operation software systems across its dental hospitals[18] - The company plans to allocate approximately 28.6% of its net proceeds (RMB 21.5 million) for potential strategic acquisitions of two dental hospitals in China by June 2024[95] - The company is planning to expand its market presence by opening two new clinics in Zhejiang province by the end of 2023[146] Capital and Assets - As of June 30, 2023, the group's current assets net value was approximately RMB 135.4 million, with a current ratio of 4.5 times[36] - The group had no bank loans as of June 30, 2023, maintaining a debt-free status[36] - The group had a bank balance of approximately RMB 147.5 million as of June 30, 2023, up from RMB 89.5 million as of December 31, 2022[36] - Total assets less current liabilities as of June 30, 2023, amounted to RMB 208,434,000, a decrease of 1.3% from RMB 211,490,000 as of December 31, 2022[107] - Non-current assets totaled RMB 73,071,000 as of June 30, 2023, down from RMB 76,211,000 at the end of 2022, reflecting a decline of 4.1%[105] Shareholder and Corporate Governance - As of June 30, 2023, the company had a total of 600,000,000 shares issued, with major shareholders JTC BVI and Ricon BVI holding 337,500,000 shares (56.25%) and 45,000,000 shares (7.5%) respectively[56] - The company adopted a share option scheme on November 8, 2022, with a maximum issuance limit of 60,000,000 shares, equivalent to 10% of the total shares issued as of the report date[61] - The company’s directors and senior management hold a combined interest of 71.25% in the company through controlled corporations[55] - The group did not recommend the payment of an interim dividend for the six months ended June 30, 2023, consistent with the previous year[129] Regulatory and Compliance Issues - The company faces risks related to the contractual arrangements, including potential regulatory changes and conflicts of interest with shareholders of the variable interest entity[87] - The company must adhere to specific regulations regarding foreign investment in medical institutions, with local partners required to hold at least 30% equity[85] - The company has received exemptions from the Stock Exchange regarding certain ongoing connected transactions under the contractual arrangements[89] - The group confirmed no significant changes in contractual arrangements with variable interest entities in the six months ending June 30, 2023[81]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 Meihao Medical Group Co., Ltd 美 皓 醫 療 集 團 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1947） 截至二零二三年六月三十日止六個月的中期業績公告 財務摘要 截至六月三十日止六個月 二零二三年 二零二二年 六月三十日 六月三十日 （人民幣千元）（人民幣千元） （未經審核） （未經審核） 收益 34,985 57,190 銷售成本 (19,517) (24,456) 毛利 15,468 32,734 除稅前（虧損）╱溢利 (2,751) 15,423 期間（虧損）╱溢利 (2,120) 10,873 期間經調整（虧損）╱溢利 (2,120) 14,408 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 Meihao Medical Group Co., Ltd 美 皓 醫 療 集 團 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1947） 有關截至二零二二年十二月三十一日止年度的年度報告的補充公告 茲提述美皓醫療集團有限公司（「本公司」）日期為二零二三年三月二十九日的公告（「該公 告」），內容有關本公司及其附屬公司（統稱「本集團」）截至二零二二年十二月三十一日止年 度的經審核綜合財務業績，及本公司截至二零二二年十二月三十一日止年度的年度報告 （「年報」）。除另有界定者外，本公告所用詞彙與該公告及年報所界定者具有相同涵義。 除該公告及年報所披露的資料外，本公司謹此向其股東及本公司潛在投資者就年報第12頁 所披露本公司於二零二二年十二月三十一日的預付款項、其他應收款項及其他資產提供以 下補充資料： 應收包銷商首次公開發售款項（「應收首次公開發售款項」）約人民幣67.1百萬元包含在本公 司 ...